Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1007772

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, if he will publish the review of risk factors and associated vulnerabilities among women recruited to the trial.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191929
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191930 191931 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

1007773

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: drugs, if he will publish the outcome of the interviews with women to explore the facilitators and barriers to accessing the HIV pre-exposure prophylaxis.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191930
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191931 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

1007775

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women have joined the HIV pre-exposure prophylaxis impact trial to date.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191931
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191930 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

1007776

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women who are victims of domestic violence have joined the HIV pre-exposure prophylaxis impact trial to date.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191932
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191930 191931 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

994107

registered interest
date	24/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish data on the average period of time between a diagnosis of HIV and initiation on antiretroviral therapy in the most recent year for which data is available.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	183408
answer	answer is ministerial correction date of answer 01/11/2018 answer text <p>Public Health England publishes data on the time interval between diagnosis of HIV and initiation of treatment. Latest available data show that in 2016 in the United Kingdom, 76% (3,214/4,225) of people newly diagnosed with HIV started treatment within 90 days of diagnosis.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 01/11/2018 16:37:22 answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth

994111

registered interest
date	24/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the level of adherence to NHS England’s Clinical Commissioning Policy on immediate antiretroviral therapy for treatment of HIV-1 in adults and adolescents since its publication in March 2018.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	183409
answer	answer is ministerial correction date of answer 01/11/2018 answer text <p>Data is not available to inform an assessment of the level of adherence to NHS England’s Clinical Commissioning Policy on immediate antiretroviral therapy for treatment of HIV-1 in adults and adolescents. This data will be published in 2019.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 01/11/2018 16:49:48 answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth

947436

registered interest
date	24/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if the Government will make it its policy to fund PrEP from central government funding for all at risk groups.
tabling member constituency	Brent Central
tabling member printed	Dawn Butler
uin	167927
answer	answer is ministerial correction date of answer 06/09/2018 answer text <p>Central government does not commission HIV, sexual health or prevention services directly. NHS England is funding the three year HIV pre-exposure prophylaxis (PrEP) Impact trial which will provide NHS England and local authority commissioners with data to inform the future commissioning of a clinically and cost effective PrEP programme. The trial began in October 2017 and full results will be available in early 2021. NHS England and local authority commissioners are already working together to use the provisional information generated by the trial to begin work to prepare for future commissioning of PrEP.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/09/2018 16:06:56 answering member 4067 label Biography information for Steve Brine
tabling member	1489 label Biography information for Dawn Butler

934317

registered interest
date	03/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress has been made on the PrEP drugs trail; and if he will make a statement.
tabling member constituency	East Kilbride, Strathaven and Lesmahagow
tabling member printed	Dr Lisa Cameron
uin	160261
answer	answer is ministerial correction date of answer 09/07/2018 answer text <p>As of 28 June 2018, 7,893 participants have been enrolled in the pre-exposure prophylaxis (PrEP) Impact Trial at 140 clinics across England. Information on participating clinics and enrolment status is regularly updated on the PreP Impact Trial website at the following link:</p><p><a href="https://www.prepimpacttrial.org.uk/join-the-trial" target="_blank">https://www.prepimpacttrial.org.uk/join-the-trial</a></p><p>A reallocation of spaces took place in May 2018 meaning 139 of the clinics are open to recruitment for gay and bisexual men with a number of the reallocated places being held centrally by the trial sponsor, so that clinics can request more if they are approaching their full allocation of places.</p><p>A proposal is also being assessed to consider increasing the total number of places available for the trial from 10,000 to 13,000. Work has begun with commissioners to prepare for future commissioning arrangements. More information on these developments can be found at the following link:</p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f03/prep-trial-updates/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f03/prep-trial-updates/</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/07/2018 16:18:57 answering member 4067 label Biography information for Steve Brine
tabling member	4412 label Biography information for Dr Lisa Cameron

923297

registered interest
date	13/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 26 April 2018 to question 136402 on HIV Infection: Drugs, if he will he make an assessment of the potential barriers to joining the PrEP Impact trial for women who are victims of domestic violence.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	153280
answer	answer is ministerial correction date of answer 21/06/2018 answer text <p>The HIV pre-exposure prophylaxis (PrEP) Impact Trial Team works together with the Trial Community Advisory Board to address issues regarding barriers to recruitment. A number of workstreams are ongoing or planned to specifically address access to the trial by women. These include a review of risk factors and associated vulnerabilities among women recruited to the trial; interviews with women to explore the facilitators and barriers to accessing PrEP; and mapping of activities across the country relating to PrEP awareness-raising among key populations including women.</p><p> </p><p>Through Public Health England’s HIV Prevention Innovation Fund, three PrEP initiatives have been funded that aim to raise awareness in underserved communities, including women.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 21/06/2018 16:06:35 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

919104

registered interest
date	07/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, which part of the NHS is responsible for HIV commissioning for the provision of drugs.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	151164
answer	answer is ministerial correction date of answer 14/06/2018 answer text <p>NHS England holds the direct commissioning responsibility for HIV drugs, and the commissioning of antiretroviral drugs is undertaken by the Specialised Commissioning teams within NHS England.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/06/2018 11:04:45 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon